Sana Biotechnology, Inc.
SANANasdaq
$3.15
↓ -0.6%Jul 17 close · end-of-day
Price
1Y↓ -27.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$872.1M
Enterprise Value
$771.0M
P/E
—
P/S
—
P/B
7.3
EV/EBITDA
—
PEG
—
FCF Yield
-15.3%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$242.0M
Free Cash Flow (TTM)
-$133.6M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-202.9%
ROIC
-1083.5%
Debt / Equity
—
Net Cash
$101.1M
Return 1Y
-29.2%
Company profile
Sana Biotechnology, Inc. focuses on utilizing engineered cells as medicines. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus. SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease.
- CEO
- Steven D. Harr
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 380
- Headquarters
- Washington
- Website
- sana.com
Management & directors
- Harr StevePresident & CEO
- Wyrick Susan D.See Remarks
Roles derived from SEC Form 4 filings.
Earnings
SANA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.17↓ -19.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$286.1M | -$356.9M | -$272.6M | -$293.1M | -$272.7M | -$250.3M |
| Net income | -$285.3M | -$355.9M | -$269.5M | -$283.3M | -$266.8M | -$244.2M |
| Diluted EPS | -$21.92 | -$2.14 | -$1.43 | -$1.46 | -$1.16 | -$0.96 |
| Operating cash flow | -$138.0M | -$251.1M | -$290.1M | -$253.6M | -$223.2M | -$143.8M |
| Free cash flow | -$161.9M | -$280.9M | -$310.9M | -$273.6M | -$256.6M | -$144.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$49.4M | -$61.8M | -$50.9M | -$50.6M | -$95.0M | -$43.5M | -$61.2M | -$48.6M |
| Net income | -$50.3M | -$59.9M | -$49.1M | -$49.4M | -$93.8M | -$42.2M | -$58.8M | -$47.2M |
| Diluted EPS | -$0.21 | -$0.25 | -$0.21 | -$0.21 | -$0.39 | -$0.16 | -$0.20 | -$0.17 |
| Operating cash flow | -$58.5M | -$51.8M | -$47.2M | -$48.7M | -$33.1M | -$29.4M | -$32.6M | -$37.4M |
| Free cash flow | -$71.6M | -$55.9M | -$47.6M | -$48.8M | -$33.2M | -$29.5M | -$33.5M | -$37.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 16, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-06 | Bishop Hans Edgar | Award | 6,297 | $0.00 | $0.00 | filing |
| 2026-04-06 | Bishop Hans Edgar | Award | 7,763 | $0.00 | $0.00 | filing |
| 2026-03-09 | Harr Steve· President & CEO | Tax withholding | 12,819 | $3.10 | $39,738.90 | filing |
| 2026-03-09 | Harr Steve· President & CEO | Tax withholding | 11,526 | $3.13 | $36,076.38 | filing |
| 2026-03-09 | Wyrick Susan D.· See Remarks | Tax withholding | 3,342 | $3.13 | $10,460.46 | filing |
| 2026-03-09 | Wyrick Susan D.· See Remarks | Tax withholding | 1,045 | $3.10 | $3,239.50 | filing |
| 2026-03-07 | Harr Steve· President & CEO | Option exercise | 50,000 | $0.00 | $0.00 | filing |
| 2026-03-07 | Wyrick Susan D.· See Remarks | Option exercise | 3,250 | $0.00 | $0.00 | filing |
| 2026-03-06 | Wyrick Susan D.· See Remarks | Option exercise | 10,416 | $0.00 | $0.00 | filing |
| 2026-03-06 | Harr Steve· President & CEO | Option exercise | 41,666 | $0.00 | $0.00 | filing |
| 2026-03-03 | Wyrick Susan D.· See Remarks | Tax withholding | 491 | $3.91 | $1,919.81 | filing |
| 2026-03-02 | Wyrick Susan D.· See Remarks | Option exercise | 1,525 | $0.00 | $0.00 | filing |
| 2026-01-05 | Wyrick Susan D.· See Remarks | Tax withholding | 2,407 | $4.27 | $10,277.89 | filing |
| 2026-01-05 | Bishop Hans Edgar | Award | 6,157 | $0.00 | $0.00 | filing |
| 2026-01-02 | Wyrick Susan D.· See Remarks | Option exercise | 7,500 | $0.00 | $0.00 | filing |
| 2025-12-15 | Wyrick Susan D.· See Remarks | Tax withholding | 873 | $5.22 | $4,557.06 | filing |
| 2025-12-13 | Wyrick Susan D.· See Remarks | Option exercise | 3,400 | $0.00 | $0.00 | filing |
| 2025-10-06 | Bishop Hans Edgar | Award | 5,628 | $0.00 | $0.00 | filing |
| 2025-07-07 | Bishop Hans Edgar | Award | 7,842 | $0.00 | $0.00 | filing |
Latest 19 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.